| EGFR突变肺癌脑膜转移奥希替尼加量治疗1例 |
| |
| 引用本文： | 赵隽,韩宇,李全福,金高娃.EGFR突变肺癌脑膜转移奥希替尼加量治疗1例[J].肿瘤药学,2021,11(6):779-782. |
| |
| 作者姓名： | 赵隽 韩宇 李全福 金高娃 |
| |
| 作者单位： | 1.鄂尔多斯市中心医院，肿瘤内科，内蒙古 鄂尔多斯，017000;2.鄂尔多斯市中心医院，呼吸科，内蒙古 鄂尔多斯，017000 |
| |
| 摘 要： | 非小细胞肺癌（NSCLC）脑膜转移患者的生存期短，治疗方法有限。奥希替尼是第三代表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI），可高效抑制EGFR敏感突变和EGFR T790M耐药突变，同时对EGFR突变的NSCLC软脑膜转移患者也有很好的疗效。本文报道1例奥希替尼加量至160 mg·d-1治疗EGFR突变肺腺癌脑膜转移，为临床治疗NSCLC难治性软脑膜转移提供参考。
|
| 关 键 词： | 奥希替尼 脑膜转移 非小细胞肺癌 EGFR突变 |
| 收稿时间： | 2020/7/28 0:00:00 |
EGFR mutation lung cancer with leptomeningeal metastasis treated with increased dosage of osimertinib: a case report |
| |
| ZHAO Jun,HAN Yu,LI Quanfu,JIN Gaowa.EGFR mutation lung cancer with leptomeningeal metastasis treated with increased dosage of osimertinib: a case report[J].Anti-Tumor Pharmacy,2021,11(6):779-782. |
| |
| Authors: | ZHAO Jun HAN Yu LI Quanfu JIN Gaowa |
| |
| Institution: | 1.Department of Oncology, Ordos Central Hospital, Ordos, Inner Mongolia, 017000, China;2.Department of Respiratory, Ordos Central Hospital, Ordos, Inner Mongolia, 017000, China |
| |
| Abstract: | Non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM) have short survival and limited treatment. Osimertinib, the 3rd-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), can selectively and effectively inhibit both EGFR and T790M mutations. It also has shown promising activity in NSCLC patients with LM and EGFR mutation. Here we reported a case of successful treatment with an increase of osimertinib to 160 mg·d-1 for a NSCLC patient with LM and EGFR mutation, hoping to provide a reference for clinical NSCLC refractory LM. |
| |
| Keywords: | Osimertinib Leptomeningeal metastases Non-small cell lung cancer EGFR mutation |
|
| 点击此处可从《肿瘤药学》浏览原始摘要信息 |
| 点击此处可从《肿瘤药学》下载免费的PDF全文 |
|
